Comprehensive Overview

The group is an ophthalmic pharmaceutical company spun off from Lee's Pharmaceuticals (950.HK). It is committed to the research, development and commercialization of ophthalmic treatments. It has also established a comprehensive ophthalmic drug pipeline with 25 drug candidates. Its cyclosporin A eye gel for the treatment of severe dry eyes will submit a new drug application to the National Drug Administration in the fourth quarter, and plans to submit simplified new drug applications for the remaining nine generic drugs within the next three years.

Risk Factors

There is a high risk in the pharmaceutical industry where the group is located. Since its establishment, it has already caused a large amount of operating losses. It is foreseeable that operating losses will continue to occur in the future, and profits may not be realized from beginning to end. Business and financial prospects are largely determined by the success of the group's drug candidates. The candidate drug development process is long, expensive, and the results are full of uncertainty. If the development and commercialization of candidate drugs is not successfully completed, or serious delays occur, the business may be seriously affected.